Metabolic liver disease cases set to reach 1.8 billion globally by 2050

A major global health warning has emerged as new research suggests that metabolic liver disease could affect nearly two billion people worldwide by 2050, driven largely by rising obesity and increasing blood sugar levels.

The condition, known as metabolic dysfunction-associated steatotic liver disease (MASLD), is already one of the most widespread liver disorders globally. Current estimates indicate that around 1.3 billion people are living with the disease today, representing roughly one in six of the world’s population.

The scale of the increase is striking. In 1990, approximately 500 million people were affected. By 2023, that figure had more than doubled, and projections now suggest it will climb to 1.8 billion by mid-century.

Researchers link this rapid rise to a combination of population growth and changing lifestyles. Increasing rates of obesity, poor diet and elevated blood sugar levels are seen as the primary drivers behind the surge in cases.

High blood sugar, in particular, has been identified as the leading contributor to MASLD-related health problems, followed closely by high body mass index and smoking. These risk factors underline the strong connection between the disease and conditions such as type 2 diabetes.

Despite being so widespread, MASLD is often described as a “silent” condition. Many people experience no obvious symptoms, meaning the disease frequently goes undiagnosed until it is discovered during tests for other health issues.

When symptoms do appear, they can include fatigue, general discomfort and pain in the upper right side of the abdomen. However, by the time these signs emerge, the condition may already have progressed.

The long-term risks associated with MASLD are significant. If left unmanaged, it can lead to serious complications including liver cirrhosis and cancer. This makes early detection and prevention particularly important.

The study also highlights demographic patterns in how the disease affects populations. While it is more common in men and tends to have higher prevalence rates among older adults, the largest number of cases is found among younger age groups. This suggests that the condition is increasingly affecting people during their working years.

Regional differences are also evident. Areas such as North Africa and the Middle East report higher prevalence rates, although increases have been recorded across the globe. In the UK, for example, cases have risen by a third since 1990, marking one of the largest increases in western Europe.

Interestingly, while the number of people diagnosed with MASLD continues to grow, the overall health burden has remained relatively stable. Researchers believe this reflects improvements in treatment and care, allowing people to manage the condition more effectively and live longer.

However, experts caution that this does not reduce the seriousness of the trend. With more people living with early-stage disease, there is a growing risk that large numbers could develop more severe complications in the future.

The findings underscore the need for greater awareness and preventive measures. Lifestyle changes, including maintaining a healthy weight, managing blood sugar levels and adopting a balanced diet, are considered key to reducing the risk.

Health experts are calling for stronger public health strategies to address the underlying causes, particularly as the condition increasingly affects younger populations.

As the numbers continue to rise, MASLD is emerging not just as a medical issue but as a major global health challenge. Without significant intervention, its impact is expected to expand further in the decades ahead, placing increasing pressure on healthcare systems worldwide.